The Complexity of Myeloid-Derived Suppressor Cells in Non-small Cell Lung Cancer: A Combinatorial Multiplex IHC and Flow Cytometry Approach

In Situ Multiplex Analysis of Regulatory and Effector T Cells in Multiple Tumor Types

A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry

In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?

With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials. 

Watch our webinar now!

A Single Picture Does Not Say It All: A Case for Comprehensive Biomarker Use in Cancer Research

During the Virtual Biomarkers Congress Eitan Akirav presented A Single Picture Does Not Say It All, a case for comprehensive biomarker use within oncology research. Did you miss out on his presentation during the conference? Now you can submit the form below to watch it at your own leisure!

Nonnegotiable Central Laboratory Capabilities for I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated clinical laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next generation sequencing.

Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing from Exploratory Research to Clinical Trials

Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?

Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.

In Situ Multiplex Analysis of Resident Microglia and Infiltrating Macrophages in Glioblastoma

Multiplex Immunofluorescence Detection of Resident Memory T Cells in Solid Tumors

Multiple Myeloma – Efficacy and Safety of 2 Different Combination Therapies

DIRA – Assay Testing for Daratumumab Clinical Trials